Crinetics Pharmaceuticals, Inc. (CRNX) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Welcome to Chronetics Pharmaceuticals' fourth quarter and full year 2025 financial results conference call. At this time, all participants are in listen-only mode. Following management's prepared remarks, we will hold a question and answer session. In order to ask a question, please press star then one on your telephone. I'd now like to turn the call over to Gayathri Tawaka, Head of Investor Relations. Please go ahead. Thank you, Operator. Good afternoon, everyone, and thank you for joining us to discuss the fourth quarter and four-year 2025 results. Today on the call, we have Dr. Scott Struthers, Founder and Chief Executive Officer, Dr. Alan Krasner, Chief Endocrinologist, and Toby Schoke, Chief Financial Officer. Also joining for the Q&A portion will be Isabel Califonos, Chief Commercial Officer. Please note there's a slide deck for today's presentation, which is in the Events and Presentations section of the Investors page on the Kinetics website. In addition, a press release was issued earlier today and is also available on the corporate website. As a reminder, we'll be making forward-looking statements, and I invite you to learn more about the risks and uncertainties associated with these statements as disclosed in our SEC filings. Such forward-looking statements are not a guarantee of performance, and the company's actual results could differ materially from those stated or implied in such statements due to risks and uncertainties associated with the company's business. In particular, today we will be reviewing launch progress to date, our commercialization plan, as well as estimates relating to market size, future performance, and other data about the acromegaly market, which are all necessarily subject to a high degree of uncertainty and risk. These forward-l...